GeoVax to Showcase Innovative COVID 19 Vaccine Data at the Keystone Symposia on Vaccinology
ATLANTA, GA - June 4, 2025 ( NEWMEDIAWIRE ) - GeoVax Labs, Inc. (Nasdaq: GOVX), a clinical-stage biotechnology company developing multi-antigen vaccines and immunotherapies, today announced that members of its scientific team and academic collaborators will present two pivotal poster presentations at the upcoming Keystone Symposia on Vaccinology: Horizons Across Disease, Demography and Technology, June 4-7, 2025, in Washington DC. These presentations, sharing data advancing GeoVax's portfolio in the battle against COVID‑19 and emerging variants, will be featured in the following sessions:
'These presentations underscore our commitment to advancing innovative MVA-vaccine vector-based strategies to optimally target the continually evolving SARS-CoV2 virus,' said Mark Newman, PhD, Chief Scientific Officer at GeoVax. 'The data we are sharing at the Keystone conference showcase the importance of inducing broadly specific immune responses, specifically T-cell responses to both the Spike and Nucleocapsid viral proteins. We envision use of this type of vaccine in populations where first-generation products have failed to induce optimally efficacious responses, including multiple types of immunocompromised patients.'
GeoVax's participation at Keystone further demonstrates its leadership in leveraging next‑generation technologies to combat infectious diseases and reinforce preparedness against emerging variants. The event will bring together experts and innovators from across the globe to discuss the latest advancements in the field. For more information on the Keystone Conference, please visit the Keystone Symposia website: https://www.keystonesymposia.org/conferences/conference-listing/meeting/onpage-program/g12025
About GeoVax
GeoVax Labs, Inc. is a clinical-stage biotechnology company developing novel vaccines against infectious diseases and therapies for solid tumor cancers. The Company's lead clinical program is GEO-CM04S1, a next-generation COVID-19 vaccine currently in three Phase 2 clinical trials, being evaluated as (1) a primary vaccine for immunocompromised patients such as those suffering from hematologic cancers and other patient populations for whom the current authorized COVID-19 vaccines are insufficient, (2) a booster vaccine in patients with chronic lymphocytic leukemia (CLL) and (3) a more robust, durable COVID-19 booster among healthy patients who previously received the mRNA vaccines. In oncology the lead clinical program is evaluating a novel oncolytic solid tumor gene-directed therapy, Gedeptin(R), having recently completed a multicenter Phase 1/2 clinical trial for advanced head and neck cancers. The Company is also developing GEO-MVA, a vaccine targeting Mpox and smallpox. GeoVax has a strong IP portfolio in support of its technologies and product candidates, holding worldwide rights for its technologies and products. For more information about the current status of our clinical trials and other updates, visit our website: www.geovax.com.
Company Contact:
[email protected]
678-384-7220
Investor Relations Contact:
[email protected]
212-698-8696
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Los Angeles Times
3 minutes ago
- Los Angeles Times
CDC shooter died from a self-inflicted gunshot wound, Georgia investigators say
ATLANTA — The man who fired more than 180 shots with a long gun at the headquarters of the U.S. Centers for Disease Control and Prevention broke into a locked safe to get his father's weapons and wanted to send a message against COVID-19 vaccines, authorities said Tuesday. Documents found in a search of the suspect's home 'expressed the shooter's discontent with the COVID-19 vaccinations,' Georgia Bureau of Investigation Director Chris Hosey said. White had written about wanting make 'the public aware of his discontent with the vaccine,' he said. Patrick Joseph White, 30, also had recently verbalized thoughts of suicide, which led to law enforcement being contacted several weeks before the shooting, Hosey said. He died at the scene Friday of a self-inflicted gunshot wound after killing a police officer. The suspect's family was fully cooperating with the investigation, authorities said at the Tuesday news briefing. White had no known criminal history, Hosey said. Executing a search warrant at White's home, authorities recovered written documents that are being analyzed, and seized electronic devices that are undergoing a forensic examination, the agency said. Investigators also recovered a total of five firearms, including a gun that belonged to his father that he used in the attack, Hosey said. Hosey said the suspect did not have a key to the gun safe, Hosey said. 'He broke into it,' he said. More than 500 shell casings have been recovered from the crime scene, the GBI said. In the aftermath, officials at the CDC are assessing the security of the campus and making sure they notify officials of any new threats. The shooting Friday broke about 150 windows across the CDC campus, with bullets piercing 'blast-resistant' windows and spattering glass shards into numerous rooms, and pinned many employees down during the barrage. White had been stopped by CDC security guards before driving to a pharmacy across the street, where he opened fire from a sidewalk, authorities said. U.S. Health Secretary Robert F. Kennedy Jr. toured the CDC campus on Monday, accompanied by Deputy Secretary Jim O'Neill and CDC Director Susan Monarez, according to a health agency statement. Kennedy also visited the DeKalb County Police Department, and later met privately with the slain officer's wife. 'No one should face violence while working to protect the health of others,' Kennedy said in a statement Saturday. It said top federal health officials are 'actively supporting CDC staff.' He did not speak to the media during his visit Monday. Some unionized CDC employees called for more protections against attack. Kennedy was a leader in a national anti-vaccine movement before President Donald Trump selected him to oversee federal health agencies, and has made false and misleading statements about the safety and effectiveness of about COVID-19 shots and other vaccines. Years of false rhetoric about vaccines and public health was bound to 'take a toll on people's mental health,' and 'leads to violence,' said Tim Young, a CDC employee who retired in April.
Business Wire
3 minutes ago
- Business Wire
Lightning Step Ranks No. 1100 on the 2025 Inc. 5000 List of America's Fastest-Growing Private Companies
HOUSTON--(BUSINESS WIRE)-- Inc. Magazine, the leading media brand and playbook for the entrepreneurs and business leaders shaping our future, today announced that Lightning Step has earned its listing in the annual Inc. 5000 list of the fastest-growing private companies in America. The Inc. 5000 provides a data-driven snapshot of the most successful companies within the economy's most dynamic segment, its independent, entrepreneurial businesses. Past honorees include Microsoft, Meta, Chobani, Under Armour, Timberland, Oracle, and Patagonia. Lightning Step joins the 2025 Inc. 5000 list, proving that innovation and impact go hand in hand. Share 'This milestone isn't just about numbers, it's about the impact we're making in behavioral healthcare,' said Brent Michael, CEO of Lightning Step. 'We're growing fast because we solve real problems. Our AI-driven, all-in-one EMR, CRM, and RCM platform helps treatment centers streamline operations so they can focus on what matters most: patient care.' This year's Inc. 5000 companies achieved impressive growth despite facing economic headwinds; including rising inflation, workforce challenges, and ongoing market volatility. Among the top 500, the median revenue growth over three years reached 1,552%, and together, these businesses contributed more than 48,000 new jobs to the U.S. economy. For the full list, company profiles, and a searchable database by industry and location, visit: 'Making the Inc. 5000 is always a remarkable achievement, but earning a spot this year speaks volumes about a company's tenacity and clarity of vision,' says Mike Hofman, editor-in-chief of Inc. 'These businesses have thrived amid rising costs, shifting global dynamics, and constant change. They didn't just weather the storm; they grew through it, and their stories are a powerful reminder that the entrepreneurial spirit is the engine of the U.S. economy.' Lightning Step has quickly become the trusted platform for behavioral health organizations across the country. Lightning Step ranked No. 25 in the Houston metro area and No. 126 in Texas. Within the software industry, it placed No. 116. This year, the company launched LIA, an AI-powered assistant for treatment centers; expanded its enterprise product suite; and significantly increased its client base, solidifying its position as an innovation tech leader transforming behavioral healthcare. About Lightning Step Lightning Step, founded by former treatment center owners, operators, and clinicians, provides a comprehensive CRM, EMR, and RCM platform purpose-built for behavioral health and addiction treatment facilities. Guided by our vision, 'Elevating care, together,' we empower behavioral health professionals to help people on their healing journeys. As a fully integrated solution for managing the complete lifecycle of patient care, Lightning Step streamlines interdepartmental workflows, enhances operational efficiency, and improves clinical outcomes. Learn more at
Yahoo
22 minutes ago
- Yahoo
Bank of England cuts gilt holdings by £32.5bn in second quarter
The report included updated projections of future APF cash flows under a range of scenarios. The estimates remain highly sensitive to future bank Rate paths and the pace of gilt unwind. nwind £100bn of UK government bond holdings between October 2024 and September 2025. The APF was introduced in 2009 as part of its quantitative easing strategy during the global financial crisis, and expanded significantly during the COVID-19 pandemic. Gilts held under the facility peaked at around £875bn in 2022 before the MPC shifted toward reducing the balance sheet. According to the latest quarterly report published on Tuesday, a total reduction of £32.5bn in gilt holdings was recorded from April to June 2025. Re Read more: FTSE 100 LIVE: Stocks mixed as US and China extend 90-day tariff truce This includes £2.9bn from outright sales and a further £29.6bn from maturing gilts. As a result, the total stock of gilts held for monetary policy purposes stood at £590bn as of 30 June, down from £622.5bn at the end of the first quarter. Threadneedle Street held three gilt sale operations during April alone, and has already published the schedule for third-quarter gilt sales on 20 June, to continue to reduce its balance sheet. The report included updated projections of future APF cash flows under a range of scenarios. The estimates remain highly sensitive to future bank rate paths and the pace of gilt unwind. Assuming the current £100bn annual pace, the net present value of cumulative cash flows is estimated at around -£115bn, the report said. It comes as the BoE cut interest rates to 4% last week, the fifth cut in a year, as the UK economy struggles amid high inflation and a stagnant jobs market. The 25 basis point reduction is expected to ease pressure on mortgage holders and homebuyers, potentially unlocking more affordable borrowing options. Read more: Oil prices rise after Trump extends China tariff truce This move brings borrowing costs back to levels not seen since March 2023, the lowest in two years. The MPC voted by a majority of 5–4 to reduce the bank rate by 0.25 percentage points, to 4%, rather than maintaining it at 4.25%. Andrew Bailey, BoE governor, said on Thursday: 'We've cut interest rates today, but it was a finely balanced decision. Interest rates are still on a downward path, but any future rate cuts will need to be made gradually and carefully.' The unprecedented split saw governor Bailey force the monetary policy committee to vote twice after a deadlocked initial vote. It was the first time in MPC history that the committee had to hold two rate in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
